261 related articles for article (PubMed ID: 18596934)
1. Why the NIH Trial to Assess Chelation Therapy (TACT) should be abandoned.
Atwood KC; Woeckner E; Baratz RS; Sampson WI
Medscape J Med; 2008 May; 10(5):115. PubMed ID: 18596934
[TBL] [Abstract][Full Text] [Related]
2. Design of the Trial to Assess Chelation Therapy (TACT).
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Drisko JA; Lee KL
Am Heart J; 2012 Jan; 163(1):7-12. PubMed ID: 22172430
[TBL] [Abstract][Full Text] [Related]
3. Chelation therapy in cardiovascular disease: an update.
Sultan S; Murarka S; Jahangir A; Mookadam F; Tajik AJ; Jahangir A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):843-854. PubMed ID: 28597699
[TBL] [Abstract][Full Text] [Related]
4. The effect of EDTA-based chelation on patients with diabetes and peripheral artery disease in the Trial to Assess Chelation Therapy (TACT).
Ujueta F; Arenas IA; Escolar E; Diaz D; Boineau R; Mark DB; Golden P; Lindblad L; Kim H; Lee KL; Lamas GA
J Diabetes Complications; 2019 Jul; 33(7):490-494. PubMed ID: 31101487
[TBL] [Abstract][Full Text] [Related]
5. Chelation therapy to prevent diabetes-associated cardiovascular events.
Diaz D; Fonseca V; Aude YW; Lamas GA
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):258-266. PubMed ID: 29846236
[TBL] [Abstract][Full Text] [Related]
6. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial.
Lamas GA; Goertz C; Boineau R; Mark DB; Rozema T; Nahin RL; Lindblad L; Lewis EF; Drisko J; Lee KL;
JAMA; 2013 Mar; 309(12):1241-50. PubMed ID: 23532240
[TBL] [Abstract][Full Text] [Related]
7. Letter to the editor concerning article "Design of the Trial to Assess Chelation Therapy (TACT)".
Ernst E
Am Heart J; 2012 Dec; 164(6):e23; author reply e25. PubMed ID: 23194497
[No Abstract] [Full Text] [Related]
8. Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review.
Mathew RO; Schulman-Marcus J; Nichols EL; Newman JD; Bangalore S; Farkouh M; Sidhu MS
Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):619-625. PubMed ID: 29129003
[TBL] [Abstract][Full Text] [Related]
9. Chelation therapy.
Harv Heart Lett; 2002 Apr; 12(8):5-7. PubMed ID: 11959517
[No Abstract] [Full Text] [Related]
10. Chelation-therapy heart trial draws fire.
Callaway E
Nature; 2012 Nov; 491(7424):313-5. PubMed ID: 23151555
[No Abstract] [Full Text] [Related]
11. Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT).
Escolar E; Ujueta F; Kim H; Mark DB; Boineau R; Nahin RL; Goertz C; Lee KL; Anstrom KJ; Lamas GA
J Diabetes Complications; 2020 Aug; 34(8):107616. PubMed ID: 32446881
[TBL] [Abstract][Full Text] [Related]
12. EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.
Ouyang P; Gottlieb SH; Culotta VL; Navas-Acien A
Curr Cardiol Rep; 2015 Nov; 17(11):96. PubMed ID: 26364188
[TBL] [Abstract][Full Text] [Related]
13. The trial to assess chelation therapy 2 (TACT2): Rationale and design.
Lamas GA; Anstrom KJ; Navas-Acien A; Boineau R; Kim H; Rosenberg Y; Stylianou M; Jones TLZ; Joubert BR; Santella RM; Escolar E; Aude YW; Fonseca V; Elliott T; Lewis EF; Farkouh ME; Nathan DM; Mon AC; Gosnell L; Newman JD; Mark DB;
Am Heart J; 2022 Oct; 252():1-11. PubMed ID: 35598636
[TBL] [Abstract][Full Text] [Related]
14. EDTA chelation therapy in the treatment of vascular disease.
Chappell LT; Janson M
J Cardiovasc Nurs; 1996 Apr; 10(3):78-86. PubMed ID: 8820322
[TBL] [Abstract][Full Text] [Related]
15. A TACTful reappraisal of chelation therapy in cardiovascular disease.
Sidhu MS; Saour BM; Boden WE
Nat Rev Cardiol; 2014 Mar; 11(3):180-3. PubMed ID: 24343569
[TBL] [Abstract][Full Text] [Related]
16. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.
Peguero JG; Arenas I; Lamas GA
Trends Cardiovasc Med; 2014 Aug; 24(6):232-40. PubMed ID: 25106084
[TBL] [Abstract][Full Text] [Related]
17. Potential Role of Metal Chelation to Prevent the Cardiovascular Complications of Diabetes.
Calderon Moreno R; Navas-Acien A; Escolar E; Nathan DM; Newman J; Schmedtje JF; Diaz D; Lamas GA; Fonseca V
J Clin Endocrinol Metab; 2019 Jul; 104(7):2931-2941. PubMed ID: 30869793
[TBL] [Abstract][Full Text] [Related]
18. Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial.
Mark DB; Anstrom KJ; Clapp-Channing NE; Knight JD; Boineau R; Goertz C; Rozema TC; Liu DM; Nahin RL; Rosenberg Y; Drisko J; Lee KL; Lamas GA;
Circ Cardiovasc Qual Outcomes; 2014 Jul; 7(4):508-16. PubMed ID: 24987051
[TBL] [Abstract][Full Text] [Related]
19. EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.
Born T; Kontoghiorghe CN; Spyrou A; Kolnagou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):11-7. PubMed ID: 22991933
[TBL] [Abstract][Full Text] [Related]
20. By the way, doctor. I get mail extolling the virtues of chelation therapy. The claim is that it removes calcium and other metals from the walls of arteries. The key element appears to be EDTA. Since vinegar is also primarily acetic acid, I'm curious whether it could have the same effect.
Komaroff AL
Harv Health Lett; 2004 Mar; 29(5):8. PubMed ID: 15044137
[No Abstract] [Full Text] [Related]
[Next] [New Search]
